Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITCH: Chemo-Immunotherapy with Tocilizumab in Recurrent Ovarian Cancer
NCT01637532Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2011
- Primary completion
- Sep 2013
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab in ovarian cancer (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Feasibility to combine carboplatin and PLD or doxorubicin with tocilizumab and Peg-Intron at 2 years. Started Feb 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01637532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01637532.